1-20 of 68
Peter Rossing
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

523-P: Proteomic Predictors of Diabetic Foot Ulcer Healing Time

TARUNVEER SINGH AHLUWALIA, SIDDHI JAIN, MARIJA PETKOVIC, JANA A. RAGUZ, GURJEET KAUR, ROSA R. JERSIE-CHRISTENSEN, KLAUS KIRKETERP-MØLLER, JONAS H. ANDERSEN, ANDERS G. PEDERSEN, ARISTIDIS VEVES, ANNE RASMUSSEN, LOUISE T. DALGAARD, PETER ROSSING
Journal: Diabetes
Diabetes 2024;73(Supplement_1):523-P
https://doi.org/10.2337/db24-523-P
Published: 14 June 2024
View articletitled, 523-P: Proteomic Predictors of Diabetic Foot Ulcer Healing Time
Meeting Abstracts

1338-P: Low Birthweight Is Associated with Elevated Risk of Chronic Kidney Disease in Type 2 Diabetes—A Follow-up Study of Persons Diagnosed with Type 2 Diabetes in the DD2 Cohort

ALEKSANDER LÜHR HANSEN, CHRISTIAN FYNBO CHRISTIANSEN, CHARLOTTE BRØNS, LEONIE M. ENGELHARD, TORBEN HANSEN, JENS S. NIELSEN, PETER VESTERGAARD, KURT HOJLUND, NIELS JESSEN, MICHAEL HECHT OLSEN, HENRIK T. SØRENSEN, PETER ROSSING, REIMAR W. THOMSEN, ALLAN A. VAAG
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1338-P
https://doi.org/10.2337/db24-1338-P
Published: 14 June 2024
View articletitled, 1338-P: Low Birthweight Is Associated with Elevated Risk of Chronic Kidney Disease in Type 2 Diabetes—A Follow-up Study of Persons Diagnosed with Type 2 Diabetes in the DD2 Cohort
Meeting Abstracts

909-P: Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY

HENRIK MAAGENSEN, JOHANNE S. JENSEN, STINE OFFERSGAARD HØYERUP, ANNE CATHRINE B. THUESEN, JESPER KROGH, PETER ROSSING, TORBEN HANSEN, FILIP K. KNOP, SOFIE HAEDERSDAL, TINA VILSBØLL
Journal: Diabetes
Diabetes 2024;73(Supplement_1):909-P
https://doi.org/10.2337/db24-909-P
Published: 14 June 2024
View articletitled, 909-P: Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY
Meeting Abstracts

1379-P: Detection of Type 2 Diabetes—Evidence from a Pilot Screening Study in Denmark

NURIA CAYUELAS MATEU, PETER ROSSING, KIRSTEN P. NEERGAARD, TANJA THYBO
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1379-P
https://doi.org/10.2337/db24-1379-P
Published: 14 June 2024
View articletitled, 1379-P: Detection of Type 2 Diabetes—Evidence from a Pilot Screening Study in Denmark
Meeting Abstracts

826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5

PETER ROSSING, MALIK BENAMAR, ALICE Y.Y. CHENG, CHRISTIAN LAUGESEN, PERNILLE HØJLUND NIELSEN, HARPREET S. BAJAJ
Journal: Diabetes
Diabetes 2024;73(Supplement_1):826-P
https://doi.org/10.2337/db24-826-P
Published: 14 June 2024
View articletitled, 826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5
Meeting Abstracts

129-OR: Increased Triglyceride Levels Are Associated with a Distinct Lipid-Associated Protein Biomarker Profile of Diabetic Foot Ulcers

MARIJA PETKOVIC, JANA A. RAGUZ, ANNE RASMUSSEN, KLAUS KIRKETERP-MØLLER, ROSA R. JERSIE-CHRISTENSEN, JONAS H. ANDERSEN, THOMAS KÜMLER, PETER ROSSING, ARISTIDIS VEVES, LOUISE T. DALGAARD, TARUNVEER SINGH AHLUWALIA
Journal: Diabetes
Diabetes 2024;73(Supplement_1):129-OR
https://doi.org/10.2337/db24-129-OR
Published: 14 June 2024
View articletitled, 129-OR: Increased Triglyceride Levels Are Associated with a Distinct Lipid-Associated Protein Biomarker Profile of Diabetic Foot Ulcers
Journal Articles

Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With Albuminuria

Ida Kirstine Bull Rasmussen, Anne-Cathrine Skriver-Moeller, Rasmus Sejersten Ripa, Philip Hasbak, Victor Soendergaard Wasehuus, Katra Hadji-Turdeghal, Emilie Hein Zobel, Martin Lyngby Lassen, Lene Holmvang, Piotr Slomka, Peter Rossing, Andreas Kjaer, Tine Willum Hansen
Journal: Diabetes
Diabetes 2024;73(3):490–496
https://doi.org/10.2337/db23-0529
Published: 22 November 2023
View articletitled, Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With Albuminuria
Open the PDF for Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With Albuminuria in another window
Journal Articles

Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes

Asger Wretlind, Viktor R. Curovic, Tommi Suvitaival, Simone Theilade, Nete Tofte, Signe A. Winther, Tina Vilsbøll, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley
Journal: Diabetes
Diabetes 2023;72(10):1493–1501
https://doi.org/10.2337/db23-0052
Published: 21 July 2023
View articletitled, Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes
Open the PDF for Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes in another window
Meeting Abstracts

829-P: Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance—A FIDELITY Subgroup Analysis

THOMAS EBERT, STEFAN ANKER, LUIS M. RUILOPE, PAOLA FIORETTO, VIVIAN FONSECA, GUILLERMO UMPIERREZ, ANDREAS L. BIRKENFELD, ROBERT LAWATSCHECK, CHARLIE SCOTT, KATJA ROHWEDDER, PETER ROSSING
Journal: Diabetes
Diabetes 2023;72(Supplement_1):829-P
https://doi.org/10.2337/db23-829-P
Published: 20 June 2023
View articletitled, 829-P: Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance—A FIDELITY Subgroup Analysis
Meeting Abstracts

1460-P: Prevalence of Chronic Kidney Disease Associated with Type 1 Diabetes in the U.S.

PETER ROSSING, PER-HENRIK GROOP, RAKESH SINGH, ROBERT LAWATSCHECK, KATHERINE R. TUTTLE
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1460-P
https://doi.org/10.2337/db23-1460-P
Published: 20 June 2023
View articletitled, 1460-P: Prevalence of Chronic Kidney Disease Associated with Type 1 Diabetes in the U.S.
Meeting Abstracts

407-P: Efficacy of Finerenone in Patients with Abnormal Markers of Liver Steatosis and Fibrosis—A FIDELITY Subgroup Analysis

NIKOLAOS PERAKAKIS, STEFAN R. BORNSTEIN, ANDREAS L. BIRKENFELD, ANDREAS LINKERMANN, STEFAN ANKER, GERASIMOS FILIPPATOS, BERTRAM PITT, PETER ROSSING, LUIS M. RUILOPE, PETER KOLKHOF, ROBERT LAWATSCHECK, CHARLIE SCOTT, GEORGE BAKRIS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):407-P
https://doi.org/10.2337/db23-407-P
Published: 20 June 2023
View articletitled, 407-P: Efficacy of Finerenone in Patients with Abnormal Markers of Liver Steatosis and Fibrosis—A FIDELITY Subgroup Analysis
Meeting Abstracts

396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

ELISABETH BUUR STOUGAARD, PETER L. KRISTENSEN, URD KIELGAST, SR., HENRIK U. ANDERSEN, YASMIN H. HAMID, PETER GÆDE, ESBEN SØNDERGAARD, GRY DØRFLINGER, KAREN K. FJELDBORG, KLAVS W. HANSEN, HENRIK H. THOMSEN, THURAYA AL-IMARI, MICHAEL RØDER, PETER ROSSING, FREDERIK PERSSON
Journal: Diabetes
Diabetes 2022;71(Supplement_1):396-P
https://doi.org/10.2337/db22-396-P
Published: 01 June 2022
View articletitled, 396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes
Meeting Abstracts

394-P: Baseline Risk Markers and Visit-to-Visit Variability in Relation to Kidney Outcomes: A Post Hoc Analysis of the PERL Study

VIKTOR ROTBAIN CUROVIC, NEIL ROY, TINE W. HANSEN, LUIZA CARAMORI, DAVID CHERNEY, IAN DE BOER, IRL B. HIRSCH, ILDIKO LINGVAY, JANET B. MCGILL, SARIT POLSKY, RODICA POP-BUSUI, RONALD J. SIGAL, KATHERINE R. TUTTLE, GUILLERMO E. UMPIERREZ, AMISHA WALLIA, SYLVIA ROSAS, PETER ROSSING, THE PERL STUDY GROUP
Journal: Diabetes
Diabetes 2022;71(Supplement_1):394-P
https://doi.org/10.2337/db22-394-P
Published: 01 June 2022
View articletitled, 394-P: Baseline Risk Markers and Visit-to-Visit Variability in Relation to Kidney Outcomes: A Post Hoc Analysis of the PERL Study
Meeting Abstracts

406-P: Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Trial

NINNA H. TOUGAARD, MARIE FRIMODT-MOELLER, HANNE SALMENKARI, ELISABETH BUUR STOUGAARD, ISMO MATTILA, TINE W. HANSEN, CRISTINA LEGIDO-QUIGLEY, SOHVI HÖRKKÖ, CAROL FORSBLOM, PER-HENRIK GROOP, MARKKU LEHTO, PETER ROSSING
Journal: Diabetes
Diabetes 2022;71(Supplement_1):406-P
https://doi.org/10.2337/db22-406-P
Published: 01 June 2022
View articletitled, 406-P: Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Trial
Meeting Abstracts

16-LB: Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes

JANET B. MCGILL, RAJIV AGARWAL, STEFAN ANKER, GEORGE BAKRIS, GERASIMOS FILIPPATOS, BERTRAM PITT, LUIS M. RUILOPE, ANDREAS L. BIRKENFELD, LUIZA CARAMORI, MEIKE DANIELA BRINKER, AMER JOSEPH, ANDREA Z. LAGE, ROBERT LAWATSCHECK, CHARLIE SCOTT, PETER ROSSING
Journal: Diabetes
Diabetes 2022;71(Supplement_1):16-LB
https://doi.org/10.2337/db22-16-LB
Published: 01 June 2022
View articletitled, 16-LB: Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes
Meeting Abstracts

866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study

FREDERIK PERSSON, PETER ROSSING, NIELS JONGS, GLENN M. CHERTOW, FAN FAN HOU, PRIYA VART, JOHN J. MCMURRAY, RICARDO CORREA-ROTTER, BERGUR STEFANSSON, ROBERT D. TOTO, ANNA MARIA LANGKILDE, DAVID C. WHEELER, HIDDO L. HEERSPINK, DAPA-CKD TRIAL COMMITTEES AND INVESTIGATORS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):866-P
https://doi.org/10.2337/db22-866-P
Published: 01 June 2022
View articletitled, 866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study
Meeting Abstracts

391-P: Normalizing Glomerular Filtration Rate (GFR) Using Extracellular Volume (ECV) Instead of Body Surface Area (BSA) : Results from an Analysis of the Preventing Early Renal Loss (PERL) Trial

LEIF ERIK LOVBLOM, SEBASTIEN O. LANCTOT, DAVID M. MAAHS, PETTER BJORNSTAD, MICHAEL MAUER, LUIZA CARAMORI, SYLVIA ROSAS, PETER ROSSING, KATHERINE R. TUTTLE, RODICA POP-BUSUI, SARIT POLSKY, AMY B. KARGER, ANDRZEJ GALECKI, BRUCE A. PERKINS, DAVID CHERNEY
Journal: Diabetes
Diabetes 2022;71(Supplement_1):391-P
https://doi.org/10.2337/db22-391-P
Published: 01 June 2022
View articletitled, 391-P: Normalizing Glomerular Filtration Rate (GFR) Using Extracellular Volume (ECV) Instead of Body Surface Area (BSA) : Results from an Analysis of the Preventing Early Renal Loss (PERL) Trial
Meeting Abstracts

826-P: Effect of Finerenone on Occurrence of Vision-Threatening Events in Patients with DR

PETER ROSSING, STEFAN ANKER, JUSTUS G. GARWEG, TAKESHI OSONOI, BERTRAM PITT, SYLVIA ROSAS, LUIS M. RUILOPE, DALONG ZHU, MEIKE DANIELA BRINKER, DAVID FINIS, SERGIO LEAL, THOMAS SCHMELTER, GEORGE BAKRIS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):826-P
https://doi.org/10.2337/db22-826-P
Published: 01 June 2022
View articletitled, 826-P: Effect of Finerenone on Occurrence of Vision-Threatening Events in Patients with DR
Meeting Abstracts

21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes

VIKTOR ROTBAIN CUROVIC, MARJOLEIN Y.A. KROONEN, NIELS JONGS, TAHA SEN, EMILIE ZOBEL, TINE W. HANSEN, GOZEWIJN D. LAVERMAN, ADRIAAN KOOY, FREDERIK PERSSON, PETER ROSSING, HIDDO L. HEERSPINK
Journal: Diabetes
Diabetes 2022;71(Supplement_1):21-OR
https://doi.org/10.2337/db22-21-OR
Published: 01 June 2022
View articletitled, 21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes
Meeting Abstracts

22-OR: Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use

PETER ROSSING, STEFAN ANKER, GERASIMOS FILIPPATOS, BERTRAM PITT, LUIS M. RUILOPE, VIVIAN FONSECA, GUILLERMO E. UMPIERREZ, LUIZA CARAMORI, MARC LAMBELET, PRABHAKAR VISWANATHAN, ROBERT LAWATSCHECK, AMER JOSEPH, GEORGE BAKRIS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):22-OR
https://doi.org/10.2337/db22-22-OR
Published: 01 June 2022
View articletitled, 22-OR: Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use